Gamida Cell (NASDAQ:GMDA) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, August 6th. Analysts expect Gamida Cell to post earnings of ($0.55) per share for the quarter.

Gamida Cell (NASDAQ:GMDA) last issued its earnings results on Tuesday, May 7th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.25). On average, analysts expect Gamida Cell to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NASDAQ GMDA traded up $0.02 on Tuesday, reaching $3.96. The stock had a trading volume of 255 shares, compared to its average volume of 30,892. The firm has a 50 day simple moving average of $5.44. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.52 and a quick ratio of 6.52. Gamida Cell has a 1 year low of $3.71 and a 1 year high of $15.41. The company has a market capitalization of $91.32 million and a P/E ratio of -0.37.

GMDA has been the topic of a number of recent research reports. ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Zacks Investment Research downgraded GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $18.67.

About Gamida Cell

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

See Also: Technical Analysis of Stocks and What It Means

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with's FREE daily email newsletter.